Artwork

Kandungan disediakan oleh Levine Media Group. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Levine Media Group atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

Boosting the Power of Dendritic Cancer Vaccines

19:08
 
Kongsi
 

Manage episode 418345793 series 49047
Kandungan disediakan oleh Levine Media Group. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Levine Media Group atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

The idea of developing cancer vaccines that harness dendritic cells is not new, but Diakonos Oncology thinks it’s been able to solve the lack of efficacy that has plagued this approach. The company combines its vaccines with RNA and proteins from a patient’s tumor to trigger a robust response by tricking the immune system to recognize cancer cells as being virally infected. We spoke to Jay Hartenbach, chief operating officer of Diakonos, about its dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.

  continue reading

515 episod

Artwork
iconKongsi
 
Manage episode 418345793 series 49047
Kandungan disediakan oleh Levine Media Group. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Levine Media Group atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

The idea of developing cancer vaccines that harness dendritic cells is not new, but Diakonos Oncology thinks it’s been able to solve the lack of efficacy that has plagued this approach. The company combines its vaccines with RNA and proteins from a patient’s tumor to trigger a robust response by tricking the immune system to recognize cancer cells as being virally infected. We spoke to Jay Hartenbach, chief operating officer of Diakonos, about its dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.

  continue reading

515 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas